• Patients with cancer are at high risk of clinically relevant bleeding, regardless of anticoagulation use.

  • The occurrence of clinically relevant bleeding is associated with an increased all-cause mortality.

Abstract

Hemostatic imbalances are frequent in patients with cancer. Although cancer-associated thrombotic complications have been well characterized, data on bleeding events in patients with cancer are sparse. Therefore, we aimed to investigate the incidence, risk factors, and impact on prognosis of bleeding events in patients with cancer initiating systemic anticancer therapies in a prospective cohort study, the Vienna Cancer, Thrombosis, and Bleeding Study. The primary study outcome was defined as clinically relevant bleeding (CRB), comprising major bleeding (MB) and clinically relevant nonmajor bleeding. In total, 791 patients (48% female), with median age of 63 years (interquartile range [IQR], 54-70), with various cancer types, 65.5% stage IV, were included. Over a median follow-up of 19 months (IQR, 8.7-24.0), we observed 194 CRB events in 139 (17.6%) patients, of which 42 (30.0%) were tumor related, 64 (46.0%) gastrointestinal, and 7 (5.0%) intracerebral. The 12-month cumulative incidence of first CRB and MB was 16.6% (95% confidence interval [CI], 13.7-19.6) and 9.1% (95% CI, 6.8-11.3), respectively, in the whole cohort, and 14.4% (95% CI, 11.2-17.5) and 7.0% (95% CI, 4.7-9.2), respectively, in those without anticoagulation. Patients with head and neck cancer had the highest risk of CRB. Lower baseline hemoglobin and albumin were associated with bleeding in patients without anticoagulation. Seven (5.0%) bleeding events were fatal, of which 6 occurred in patients without anticoagulation. Patients with CRB were at an increased risk of all-cause mortality (multivariable transition hazard ratio, 5.80; 95% CI, 4.53-7.43). In patients with cancer, bleeding events represent a frequent complication and are associated with increased mortality.

1.
Mantha
S
.
Bleeding disorders associated with cancer
.
Cancer Treat Res
.
2019
;
179
:
191
-
203
.
2.
Khorana
AA
,
Mackman
N
,
Falanga
A
, et al
.
Cancer-associated venous thromboembolism
.
Nat Rev Dis Primers
.
2022
;
8
(
1
):
11
.
3.
Mulder
FI
,
Horváth-Puhó
E
,
van Es
N
, et al
.
Venous thromboembolism in cancer patients: a population-based cohort study
.
Blood
.
2021
;
137
(
14
):
1959
-
1969
.
4.
Grilz
E
,
Posch
F
,
Nopp
S
, et al
.
Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis
.
Eur Heart J
.
2021
;
42
(
23
):
2299
-
2307
.
5.
Falanga
A
,
Ay
C
,
Di Nisio
M
, et al
.
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
.
Ann Oncol
.
2023
;
34
(
5
):
452
-
467
.
6.
Key
NS
,
Khorana
AA
,
Kuderer
NM
, et al
.
Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Guideline update
.
J Clin Oncol
.
2023
;
41
(
16
):
3063
-
3071
.
7.
Trujillo-Santos
J
,
Nieto
JA
,
Ruíz-Gamietea
A
, et al
.
Bleeding complications associated with anticoagulant therapy in patients with cancer
.
Thromb Res
.
Apr 2010
;
125
(
suppl 2
):
S58
-
S61
.
8.
Yamashita
Y
,
Morimoto
T
,
Amano
H
, et al
.
Anticoagulation therapy for venous thromboembolism in the real world- from the COMMAND VTE Registry
.
Circ J
.
2018
;
82
(
5
):
1262
-
1270
.
9.
Ay
C
,
Grilz
E
,
Nopp
S
, et al
.
Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study
.
Res Pract Thromb Haemost
.
2023
;
7
(
1
):
100026
.
10.
Carrier
M
,
Abou-Nassar
K
,
Mallick
R
, et al
.
Apixaban to prevent venous thromboembolism in patients with cancer
.
N Engl J Med
.
2019
;
380
(
8
):
711
-
719
.
11.
Khorana
AA
,
Soff
GA
,
Kakkar
AK
, et al
.
Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer
.
N Engl J Med
.
2019
;
380
(
8
):
720
-
728
.
12.
de Winter
MA
,
Dorresteijn
JAN
,
Ageno
W
, et al
.
Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score
.
Thromb Haemost
.
2022
;
122
(
5
):
818
-
829
.
13.
Abdulla
A
,
Davis
WM
,
Ratnaweera
N
,
Szefer
E
,
Ballantyne Scott
B
,
Lee
AYY
.
A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer
.
Thromb Haemost
.
2020
;
120
(
4
):
702
-
713
.
14.
Schulman
S
,
Kearon
C
;
Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
.
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
.
J Thromb Haemost
.
2005
;
3
(
4
):
692
-
694
.
15.
Ay
C
,
Posch
F
,
Kaider
A
,
Zielinski
C
,
Pabinger
I
.
Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality
.
J Thromb Haemost
.
2015
;
13
(
3
):
390
-
397
.
16.
Fine
JP
,
Gray
RJ
.
A proportional hazards model for the subdistribution of a competing risk
.
J Am Stat Assoc
.
1999
;
94
(
446
):
496
-
509
.
17.
Gray
RJ
.
A class of K-sample tests for comparing the cumulative incidence of a competing risk
.
Ann Statist
.
1988
;
16
(
3
):
1141
-
1154
.
18.
Posch
F
,
Riedl
J
,
Reitter
EM
, et al
.
Hypercoagulabilty, venous thromboembolism, and death in patients with cancer. A multi-state model
.
Thromb Haemost
.
2016
;
115
(
4
):
817
-
826
.
19.
Trujillo-Santos
J
,
Nieto
JA
,
Tiberio
G
, et al
.
Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry
.
Thromb Haemost
.
2008
;
100
(
3
):
435
-
439
.
20.
Kamphuisen
PW
,
Lee
AYY
,
Meyer
G
, et al
.
Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study
.
J Thromb Haemost
.
2018
;
16
(
6
):
1069
-
1077
.
21.
Bauersachs
R
,
Lee
AYY
,
Kamphuisen
PW
, et al
.
Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism-analysis of the CATCH Study
.
Thromb Haemost
.
2018
;
118
(
5
):
914
-
921
.
22.
Vedovati
MC
,
Giustozzi
M
,
Munoz
A
, et al
.
Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism
.
Eur J Intern Med
.
2023
;
112
:
29
-
36
.
23.
Moik
F
,
Posch
F
,
Zielinski
C
,
Pabinger
I
,
Ay
C
.
Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials
.
Res Pract Thromb Haemost
.
2020
;
4
(
4
):
550
-
561
.
24.
Cohen
AT
,
Wallenhorst
C
,
Choudhuri
S
,
Nassar
A
,
Pollock
KG
,
Martinez
C
.
A novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer
.
Thromb Haemost
.
2024
;
124
(
4
):
324
-
336
.
25.
Farge
D
,
Frere
C
,
Connors
JM
, et al
.
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
.
Lancet Oncol
.
2022
;
23
(
7
):
e334
-
e347
.
26.
Patell
R
,
Gutierrez
A
,
Rybicki
L
,
Khorana
AA
.
Identifying predictors for bleeding in hospitalized cancer patients: a cohort study
.
Thromb Res
.
2017
;
158
:
38
-
43
.
27.
Mulder
FI
,
Bosch
FTM
,
Carrier
M
, et al
.
Growth differentiation factor-15 for prediction of bleeding in cancer patients
.
J Thromb Haemost
.
2022
;
20
(
1
):
138
-
144
.
28.
Bleker
SM
,
Brekelmans
MPA
,
Eerenberg
ES
, et al
.
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis
.
Thromb Haemost
.
2017
;
117
(
10
):
1944
-
1951
.
29.
Agnelli
G
,
George
DJ
,
Kakkar
AK
, et al
.
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer
.
N Engl J Med
.
2012
;
366
(
7
):
601
-
609
.
30.
McBane
RD
,
Vlazny
DT
,
Houghton
D
, et al
.
Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment
.
Thromb Haemost
.
2023
;
123
(
5
):
535
-
544
.
You do not currently have access to this content.
Sign in via your Institution